|Bid||10.00 x 800|
|Ask||0.00 x 1300|
|Day's Range||9.29 - 10.65|
|52 Week Range||2.93 - 32.05|
|Beta (5Y Monthly)||3.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.03|
Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.
Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 10:30 a.m. Eastern Standard Time. The conference will be held at the Lotte New York Palace in New York City.
Clovis Oncology, Inc. (NASDAQ: CLVS) popped 90 cents, or more than 10%, to $9.73 on 11.7 million shares Wednesday on no news. 3D Systems Corporation (NYSE: DDD) climbed 63 cents, or 5.3%, to $12.34 on 2.9 million shares Wednesday. Wednesday's move broke the stock out of a month-long wedge formation, and next resistance for the stock, which has nearly doubled in 5 months, is at $14.25.
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.
Santa Clara, California-based Silicon Valley Bank (Nasdaq: SIVB) has moved its Colorado loan production office from Broomfield to the Tabor Center at 1200 17th St. in downtown Denver. Josh Dorsey, managing director at Silicon Valley Bank who oversees the Colorado market, said the bank hopes to create a welcoming space for its clients to come visit. “When we built out this office, we had our community and clients in mind,” Dorsey said.
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
Shares of Clovis Oncology jumped in higher-than-average volume on Wednesday after U.S. regulators accepted the biotech company's application for a prostate cancer treatment.
Shares of Clovis Oncology Inc. soared 22% in very active premarket trading Wednesday, after the biopharmaceutical company said the supplemental new drug application (sNDA) for its prostate cancer treatment Rubraca has been granted priority review status by the Food and Drug Administration. Trading volume swelled to over 2.9 million shares, compared with the full-day average of 10.7 million shares. "Recently presented data suggests that Rubraca may play a meaningful role in the treatment of patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer, and this filing represents an important milestone for Clovis as it brings us one step closer to potentially making this valuable therapy available," said Chief Executive Patrick Mahaffy. "We are encouraged by the FDA's decision to grant priority review to the Rubraca application, which focuses on eligible patients with advanced prostate cancer, for whom new treatment options are very much needed." The stock has nearly tripled (up 177.7%) over the past three months through Tuesday, while the iShares Nasdaq Biotechnology ETF has advanced 18.2% and the S&P 500 has gained 9.6%.
Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2019. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures.
Clovis Oncology, Inc. (NASDAQ: CLVS) (the "Company") announced today that on January 6, 2020 it priced a registered direct offering (the "Share Offering") of an aggregate of 17,777,679 shares (the "Shares") of its common stock at a price of $9.25 per share to a limited number of holders (the "Holders") of its 4.50% Convertible Senior Notes due 2024 (the "2024 Notes"). The Company intends to use the proceeds of the Share Offering to repurchase from such Holders an aggregate of $123,417,000 principal amount of its 2024 Notes (the "Note Repurchase", and collectively with the Share Offering, the "Transactions") in privately negotiated transactions. J.P. Morgan and BofA Securities acted as the exclusive agents to the Company in connection with the Transactions.
Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA ...
The FDA accepts Immunomedics' (IMMU) BLA resubmission for sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer, having received at least two prior therapies.